Flucorta

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucorta

Property Description
Active ingredient Fluconazole
Form Tablets, Hard capsules, Oral suspension, Injection solution
Pharmacological class Systemic Antifungal Agent, Triazole class
Common purpose Control and prevention of fungal and yeast infections
Origin Synthetic (Triazole derivative)

What Type of Medicine is Flucorta and What is its Purpose?

Flucorta is a synthetic, prescription medication classified as a systemic antifungal agent used to control and prevent infections caused by fungi and yeasts. It belongs specifically to the triazole antifungal class, a chemical category of compounds.

The primary purpose of this medicine is to address and suppress fungal overgrowth by exhibiting a fungistatic effect, which stops the multiplication of the fungal cells without destroying them outright. Fluconazole, the active ingredient in Flucorta, is clinically recognized for its reliable efficacy against a broad range of fungal pathogens.


Flucorta's Active Ingredient and Available Forms

The core substance responsible for the therapeutic effect of Flucorta is the single active ingredient, Fluconazole. This synthetic molecule is defined chemically by its triazole structure (C13H12F2N6O), a property that differentiates it from older antifungal classes.

This medication is available in various dosage forms to suit different clinical needs, including solid oral preparations such as tablets and hard capsules, a liquid oral suspension, and a sterile injection solution. The availability of both oral and intravenous forms provides comprehensive delivery options, ensuring the active ingredient can be delivered effectively via oral administration or intravenous administration depending on the patient's condition.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Flucorta?

Possible Side Effects and Safety Information: Flucorta (Fluconazole)

Flucorta (fluconazole) is associated with a range of possible side effects, which are officially classified by frequency and system-organ class in regulatory documentation.

Common and Less Serious Reactions

The most commonly reported adverse reactions include headache, rash, and gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea. Transient elevations in liver enzyme levels have also been reported as common.

Serious Adverse Reactions

Serious and potentially life-threatening reactions, though rare, have been officially documented. These include severe hepatic toxicity (liver failure, sometimes fatal) and serious allergic reactions (anaphylaxis and exfoliative skin disorders). Fluconazole has also been associated with dose-related QT interval prolongation on the electrocardiogram and cases of Torsades de pointes, a serious heart rhythm disturbance.

Population-Specific Safety Considerations

Pregnancy: The use of high doses (400–800 mg/day) for prolonged periods during the first trimester has been associated with reports of a distinct and rare pattern of birth abnormalities. For short-term or low-dose use, available studies suggest a small or inconclusive risk of miscarriage or cardiac malformations. Use during pregnancy is generally limited to severe or life-threatening infections when benefits outweigh the risks.

Hepatic and Renal Impairment: Because fluconazole is eliminated primarily by the kidneys and carries a risk of hepatic toxicity, patients with impaired renal function or pre-existing liver dysfunction require caution. Dose adjustment may be necessary for patients with significantly reduced creatinine clearance.

Key Restrictions and Monitoring

Coadministration with certain drugs known to prolong the QT interval and metabolized by the enzyme CYP3A4 (such as pimozide, halofantrine, and high-dose terfenadine) is contraindicated due to the increased risk of cardiotoxicity. Patients with underlying risk factors for heart rhythm disturbances should be monitored closely. If signs or symptoms suggestive of liver dysfunction (e.g., persistent nausea, jaundice) or a severe skin reaction develop, treatment must be immediately discontinued.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Flucorta (Fluconazole) specifies distinct manifestations and mandated actions in the event of overexposure.

Overdose scope
Documented overdose presentations: Overdose has been reported to involve severe CNS effects, including hallucinations and paranoid behavior.
Physiological systems affected: Central Nervous System and Cardiovascular System.
Dose-related or exposure-related factors: Excessive exposure is associated with the risk of QT interval prolongation and the serious ventricular arrhythmia Torsade de Pointes.
Population-specific overdose notes: Individuals with impaired renal function are at an increased risk of toxicity due to the drug’s predominant renal excretion, which leads to reduced clearance.
Emergency-response statements: Seek immediate medical attention for suspected overdose. Treatment should be symptomatic and supportive.
When immediate medical help is required: Contact emergency services immediately if the individual has collapsed, experiences trouble breathing, has a seizure, or cannot be awakened.

Official Overdose Management Structure

  • No specific antidote is known for Fluconazole overdose.
  • Documented procedural measures include the consideration of gastric lavage and the use of hemodialysis, which is officially stated to reduce plasma concentrations by approximately 50% in a three-hour session.

Connection to the overall overdose profile

The regulatory profile defines severe CNS and cardiac manifestations as the critical risks of overdose, necessitating immediate emergency action. Management focuses on supportive measures and drug elimination via enhanced clearance, particularly highlighting hemodialysis as an effective, documented procedure for substance removal.

Therapeutic Uses of Flucorta

What Flucorta Treats: Main Uses and Benefits

Flucorta is a systemic antifungal medication relevant for managing various infections caused by fungi and yeasts. The uses described below are commonly recognized within the therapeutic domains of the medication.

The medication helps address conditions presenting with systemic or localized discomfort, including Candidemia, Cryptococcal Meningitis, and recurrent candidiasis of the mouth, throat, or vagina. It is applied across domains where additional symptomatic support is needed, primarily to ease challenging symptoms like persistent fevers, pain, burning, severe itching, and difficulty swallowing.

“Flucorta supports patients during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities.”

Systemic and Localized Symptom Support

Flucorta is relevant for managing severe, widespread fungal diseases, where it helps with symptoms related to systemic imbalance, and provides prophylactic support for highly vulnerable patients, such as those undergoing chemotherapy or transplantation. It supports the patient during acute or episodic manifestations by providing symptomatic relief that helps maintain a sense of stability.

Quick Fact: Relief for Mucosal Irritation
May contribute to improved comfort by easing inflammatory symptoms in recurrent candidiasis.

Eligibility and Restrictions for Use

Flucorta (Fluconazole) eligibility is strictly defined by official regulatory criteria based on patient status, age, and co-administration conditions.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated for any patient with known hypersensitivity to azole antifungals or to the drug’s excipients. Use is also strictly prohibited for patients concurrently taking certain medications known to prolong the QT interval, such as cisapride, astemizole, pimozide, or high-dose terfenadine. Furthermore, specific formulations are contraindicated for patients with rare hereditary metabolic disorders.

Populations Requiring Conditional or Restricted Use

  • Organ Function: Use is conditional in patients with impaired renal function, requiring mandatory assessment and adjustment for multi-dose therapy. Caution and close monitoring are required for those with pre-existing hepatic impairment.
  • Cardiac Status: Caution is advised for patients with pre-existing cardiovascular conditions or certain electrolyte abnormalities due to the risk of heart rhythm changes.
  • Age and Development: Use is generally established for adults and children 6 months for approved indications, though neonates require a modified administration schedule due to slower drug clearance.
  • Pregnancy/Lactation: High-dose, long-term use is not recommended during the first trimester of pregnancy due to reported risk of harm. Single-dose use is generally permitted while breastfeeding, but repeated dosing is advised against.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Flucorta (Fluconazole) is characterized by its documented effects on certain metabolic pathways and co-administered drugs, leading to specific regulatory constraints.

Classification Examples of Interacting Substances Official Interaction Effect
Contraindicated Combinations Pimozide, Quinidine, Erythromycin, Cisapride, Astemizole Co-administration is prohibited due to risk of cardiac events, including QT prolongation and Torsades de pointes.
Metabolic Inhibition Warfarin, Alfentanil, Oral Hypoglycemics, Abrocitinib Fluconazole is a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4, resulting in increased systemic exposure of substrates metabolized by these enzymes.
Exposure Modification Rifampicin, Hydrochlorothiazide Rifampicin decreases Fluconazole exposure (AUC reduced by approximately 25%). Hydrochlorothiazide increases Fluconazole plasma concentration by 40%.
Pharmacodynamic Risk Amiodarone Concomitant use with high-dose Fluconazole may result in an additive risk of QT interval prolongation.

Fluconazole does not require timing separation from food, as regulatory data shows its absorption is not clinically significantly affected by meals. The pharmacokinetics are, however, markedly affected by reduced renal function, which influences the magnitude of drug-drug interactions, as Fluconazole is primarily cleared renally. The enzyme inhibiting effect of Fluconazole persists for four to five days after its discontinuation due to the drug’s long half-life.

Mechanism of Action

Inhibition of Fungal Sterol Synthesis

The drug's primary action involves the inhibition of the fungal enzyme lanosterol 14-alpha-demethylase (14-alpha-DM). This enzyme is crucial for the ergosterol biosynthesis pathway. By binding tightly to this fungal-specific target, Fluconazole initiates a molecular cascade that prevents the formation of ergosterol, the main sterol component of the fungal cell membrane.


Disruption of Fungal Cell Membrane Integrity

The lack of essential ergosterol, coupled with the damaging accumulation of abnormal intermediate sterols, structurally compromises the fungal cell membrane. This weakens the membrane's integrity and fluidity, causing increased permeability and cellular dysfunction. This physiological consequence prevents the fungal organism from growing and replicating, resulting in a fungistatic action.


Mechanism Constraints: Fungal Resistance Pathways

Mechanism effectiveness is limited by the fungal organism's ability to activate resistance mechanisms. This occurs mainly through the upregulation of efflux pumps (transporters that actively pump the drug out of the cell) or via mutations in the gene for the target enzyme (ERG11). These resistance mechanisms prevent the drug from achieving sufficient concentration at its intended target, resulting in reduced enzyme inhibition.

Dosage and Administration Information

How to Use Flucorta (Fluconazole) — Administration Guidelines

These instructions define the methods for administering Flucorta (fluconazole) and are not clinical advice.


Administration Scope and Dosing

Administration Detail Guideline
Route of Administration Oral (Capsules/Suspension) and Intravenous (IV) Infusion.
Dose Equivalence The same dose in milligrams is used for both oral and IV routes.
Timing in Relation to Meals May be taken with or without food.
IV Infusion Rate Must not exceed 200 mg per hour (or 10 mL/minute of the 2 mg/mL solution).

Dosage and Procedural Rules

Dosing often involves a loading dose (typically twice the daily maintenance dose) administered on the first day to quickly achieve effective blood levels, followed by a lower maintenance dose.

Population/Condition Special Procedural Instruction
Pediatric Dosing Based strictly on body weight (mg/kg), with maximum daily doses clearly defined.
Renal Impairment Dosage must be reduced for patients with impaired kidney function (CrCl le 50 mL/min) after the initial loading dose.
Oral Suspension Requires reconstitution of the powder and must be shaken well before each use.

Standard schedules include single doses for acute conditions, as well as once-daily, once-weekly, or long-term monthly regimens for maintenance or suppression. If a dose is missed, take it as soon as remembered, but do not double the dose to make up for the missed one.

Recent Clinical Evidence

Clinical trials and research have examined Flucorta in research contexts involving certain respiratory and allergic conditions. Different types of studies was observed in to explore how symptoms evolve over defined time intervals and to provide context for how patients report their experience with the medication. The research examined outcomes related to physical discomfort and daily functioning.

Evidence for use in Allergic Rhinitis (Seasonal and Perennial Nasal Symptoms)

Flucorta was studied for individuals dealing with allergic rhinitis, a condition characterized by fluctuating nasal symptoms like congestion and irritation. Research suggests patterns related to measured changes in outcomes linked to inflammatory states. These findings reflect the specific conditions under which studies were conducted. Follow-up durations were limited in many trials, meaning our understanding of the stability of outcomes over many years is incomplete. Comparative evidence against all other available treatment options is also lacking.


Evidence for use in Asthma Symptoms (Preventative Treatment)

Flucorta was evaluated in individuals with asthma, a condition presenting with cycles of stability and flare-ups. Studies monitored participants to see how outcomes related to breathing difficulties and physiological strain were associated with the use of Flucorta. Research limitations exist, as sample sizes were modest in some earlier trials, and subgroup findings are uncertain regarding different forms of asthma.


Long-term studies and follow-up

Research explored how symptoms changed over extended periods. Available data describes patterns related to how symptoms evolved throughout the observation period. However, it must be noted that long-term effects are not fully established. There is limited information for long-term outcomes extending beyond a year or two, and certainty remains low.


Evidence in special populations

Flucorta was observed in studies that included children and older adults to see if outcomes reflecting daily functioning or activity level differed from the main study populations. Findings suggest that the body of evidence quality varies across studies for these groups. Data for certain groups, such as pregnant individuals or those with comorbidities, is limited, and research is ongoing.


What is still uncertain about Flucorta

Research has identified areas where findings were mixed regarding specific patient-reported outcomes. Key limitations include that the results apply only to the populations studied, meaning findings describe group patterns, not individual predictions. The research highlights what is known — and what is still uncertain regarding the evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Flucorta (FAQ)


Q: How quickly does Flucorta start to work?

According to official regulatory documents, peak concentrations in the bloodstream are typically reported to occur between 1 and 2 hours after the medicine is taken by mouth. This indicates the time it takes for the active ingredient to reach its highest level in the body.


Q: Is Flucorta safe to take with common pain relievers like ibuprofen?

Official information indicates that Flucorta may increase the overall systemic effects of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Regulatory information states that co-administration is a matter of caution due to a documented potential increase in the risk of gastrointestinal adverse events.


Q: How long does the effect of one dose of Flucorta typically last?

The length of time the active ingredient stays in the body is described by its terminal plasma elimination half-life. Official product information states this is approximately 30 hours, with a reported range between 20 to 50 hours in normal volunteers.


Q: Is Flucorta a controlled substance?

Regulatory documents generally classify Flucorta's active ingredient, fluconazole, as a prescription-only (Rx) medication. It is not categorized as a controlled substance by major regulatory bodies.


Q: Why is Flucorta often compared to other drugs ending in '-cort'?

Flucorta is classified as a synthetic triazole antifungal agent, based on its chemical structure and action. This is a distinct chemical class from the corticosteroid drugs that commonly include the suffix '-cort' in their names.


Q: How is Flucorta packaged and dispensed by the pharmacy?

The medicine is available in various forms, including tablets, hard capsules, and a powder for oral suspension. The reconstituted liquid oral suspension, for example, is officially reported to be stable for 14 days when stored within the specified temperature range.


Q: Are there any common long-term effects of using Flucorta?

For long-term use, official regulatory guidance emphasizes the necessity of close monitoring for potential effects on the liver, kidneys, and heart function. Additionally, chronic, high-dose use during the first trimester of pregnancy has been associated with reports of a rare pattern of birth defects.


Q: Is it normal to feel tired when starting Flucorta?

While fatigue is not universally listed as a common reaction, official safety information notes that unusual fatigue or weakness are symptoms that should be reported. This is because they may be a possible, though rare, sign associated with side effects such as low blood potassium or the onset of adrenal gland problems.


Q: What kinds of food or drinks should I limit while on Flucorta?

The official instructions indicate that the medicine can be taken with or without food. Regulatory studies have shown that having meals does not significantly affect the drug's absorption into the body.


Q: Is Flucorta available over the counter in some countries?

Across most major regulatory regions, this medication is categorized as a prescription-only drug. Its status requires a prescription from a licensed healthcare professional.


Q: Can Flucorta be crushed or split?

Official patient instructions for the tablet form typically state that the medicine should be swallowed whole. Patient instructions generally state that the tablets are not to be cut, broken, or chewed.


Q: Are there generic versions of Flucorta?

Yes, regulatory records confirm that generic versions of the active ingredient, fluconazole, have been approved by authorities like the FDA and are available.


Q: Does Flucorta interact with birth control pills?

Some regulatory patient information states that Fluconazole does not affect the way hormonal contraceptive pills or devices work. This is based on clinical data reviewed by regulatory bodies.


Q: Do older adults react differently to Flucorta than younger adults?

Pharmacokinetic studies in older adults indicate that the drug’s elimination half-life may be longer and its clearance lower. This may mean that a dosage adjustment is considered necessary for those older patients who also have age-related kidney function changes.


Q: Is Flucorta safe for breastfeeding women?

Official information describes that the amount of the drug excreted into breastmilk is generally less than the recommended neonatal dosage, which determines the regulatory position on use while breastfeeding.


Q: Has Flucorta been studied in children or adolescents?

Yes, regulatory documentation confirms that the medicine has been studied in children and adolescents. It is officially licensed for use in these populations for specific, approved indications, such as treating mucosal candidiasis.


Q: Will Flucorta affect the results of any laboratory blood tests?

During treatment, blood tests are often required to monitor for potential changes in body chemistry. This is done to check for unwanted effects, such as changes in liver enzyme levels or electrolyte problems, which are known effects associated with the drug.


Q: Can Flucorta be used for conditions not listed in the official documents?

Official regulatory documents, such as the FDA label or EMA SmPC, define the specific medical conditions and uses for which the drug has been approved and licensed by the governing authority.


Q: Are there any specific lifestyle changes recommended while taking Flucorta?

Official precautions advise patients to be careful when driving or operating machinery if they experience dizziness or seizures. Patients are generally informed that the use of alcohol or tobacco should be managed with their healthcare professional.


Q: How does Flucorta affect the immune system?

The primary action defined in regulatory documents is to inhibit fungal growth (fungistatic), affecting the fungal cell structure. Research has suggested that the drug may have additional immunomodulatory effects on certain human immune cells, though this is not its primary licensed mechanism.


Q: Can Flucorta cause skin rashes or sensitivity to the sun?

Regulatory documents list skin rash as one of the most common and less serious adverse reactions. Serious, potentially life-threatening skin reactions have also been officially documented and require immediate attention.


Q: How do doctors monitor a patient taking Flucorta long-term?

For patients on long-term therapy, close monitoring is generally recommended. This monitoring may include regular blood tests to check for potential changes in liver function, as specified in regulatory precautions.


Q: Is it possible for Flucorta to stop working over time?

Official documents discuss that both inherent and acquired resistance to fluconazole have been reported in fungal species. This resistance mechanism is defined as the fungal organism's ability to activate defenses that reduce the drug's effectiveness over time.


Q: Can I drive or operate machinery while taking Flucorta?

Official warnings state that occasional dizziness or seizures may occur with the medicine. Warnings state that caution is necessary when driving vehicles or operating machinery until the patient understands how the medicine affects them.


Q: Are headaches a common side effect of Flucorta?

Yes, according to official regulatory documentation, headache is listed as one of the most commonly reported adverse reactions associated with the use of Flucorta.


Q: Can alcohol consumption interfere with Flucorta?

Official patient information often directs that the use of alcohol be managed with a healthcare professional. Consumption may increase the workload on the liver, which is a key area of safety concern for this medicine.


Q: What is the half-life of Flucorta?

The terminal plasma elimination half-life of Flucorta's active ingredient is approximately 30 hours following oral administration. This value, reported in regulatory pharmacokinetic data, is a measure of how long it takes for the drug's concentration in the blood plasma to be reduced by half.

How should Flucorta be stored and disposed of?

The storage and disposal instructions for Flucorta (fluconazole) are defined by regulatory documents to ensure product stability and safety.

Storage Requirements

Fluconazole tablets and injection solutions must be stored at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F). The injection solution requires protection from light and must not be frozen. The powder for oral suspension must be kept in its tightly closed, original container.

Dosage Form Stability Note
Oral Suspension (reconstituted) Stable for 14 days when stored at or below 30 C.

All forms must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be disposed of through a drug take-back program. If this is unavailable, the drug should be mixed with an unappealing substance, sealed in a container, and placed in the household trash, strictly adhering to local regulations. The medicine should not be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucorta found in:

A-Z Index: